Supplementary Material.docx (1.41 MB)
Download file

Supplementary Material: Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005–2015): SCAN-LEAF study

Download (1.41 MB)
dataset
posted on 17.11.2021, 09:25 by Jens Benn Sørensen, Pia Horvat, Mats Rosenlund, Anne Mette Kejs, Dony Patel, Ariadna Juarez-Garcia, Laure Lacoin, Melinda J Daumont, John R Penrod, John C O’Donnell, Odd Terje Brustugun, Simon Ekman
Supplementary Figure 1. Kaplan-Meier curves for overall survival in patients with NSQ NSCLC by TNM stage and year of diagnosis in Denmark. A) Stage I, B) Stage II, C) Stage IIIA, D) Stage IIIB and E) Stage IV. Data were truncated at month 138.

Supplementary Figure 2. Kaplan-Meier curves for overall survival in patients with SQ NSCLC by TNM stage and year of diagnosis in Denmark. A) Stage I, B) Stage II, C) Stage IIIA, D) Stage IIIB and E) Stage IV. Data were truncated at month 138.

Supplementary Table 1. ICD-10 morphology codes for NSCLC.

Supplementary Table 2. Initial treatment categories and definitions. Initial treatment was defined as the first treatment received within 6 months of diagnosis, associated with any other treatment received within a certain time period following first treatment as defined in the table below

Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005–2015): SCAN-LEAF study


ABSTRACT
Aim: Describe initial treatment patterns and survival of patients diagnosed with non-small-cell lung cancer (NSCLC) in Denmark, before immune checkpoint inhibitor and later-generation tyrosine kinase inhibitor use.
Patients & methods: Adults diagnosed with incident NSCLC (2005-2015; follow-up: 2016). Initial treatments and overall survival (OS) are reported.
Results: 31,939 NSCLC patients (51.6% stage IV) were included. Increasing use of curative radiotherapy/chemoradiation for stage I&II/IIIA&IIIB NSCLC coincided with improved 2-year OS. Systemic anticancer therapy use increased for patients with stage IV non-squamous (53.0-60.6%) but not squamous (44.9-47.3%) NSCLC. One-year OS improved in patients with stage IV non-squamous (23-31%) but not squamous (22-25%) NSCLC.

Funding

Bristol Myers Squibb

History